Article/Intelligence
Warburg Pincus Working With Goldman Sachs on Potential Sale of Modernizing Medicine
Reporting: Armie Margaret Lee
Credit Research: Kyle Owusu
Warburg Pincus LLC is working with Goldman Sachs Group Inc. as it evaluates options for Modernizing Medicine Inc., including a potential sale of the healthcare technology company, according to industry sources.
Based in Boca Raton, Fla., Modernizing Medicine, or ModMed, provides medical practices with electronic medical record and practice management software and revenue cycle management services.
Reuters reported on Jan. 8 that Warburg has tapped a financial advisor to solicit interest in ModMed from potential acquirers, and a potential sale could value the company at north of $5 billion, including debt.
Warburg invested $231 million in ModMed in 2017. ModMed has completed acquisitions, including orthopedics electronic health records, or EHR, vendor Exscribe, the allergy testing and immunotherapy software of Xtract Solutions, and TRAKnet and other assets from podiatric EHR company NEMO Health.
ModMed and Warburg previously considered a partial stake sale in 2022, Axios reported.
Given the aging U.S. population’s contribution to patient admissions growth, the ongoing challenges health systems face due to an ever-changing regulatory environment, the subscription-based revenue model underlying most healthcare technology companies, high customer switching costs, and the ability potential to bring technology to bear to address tangible problems, it is unsurprising that electronic health records and revenue cycle management companies have received a lot of attention from private equity.
In 2019, Bon Secours Mercy Health sold 51% of equity in revenue cycle management company Ensemble Health to Golden Gate Capital, translating to an enterprise value of $1.8 billion, or 11.5x EBITDA. In 2022, Berkshire Partners and Warburg Pincus entered into an agreement to make an investment in Ensemble, valuing the company at about $5 billion, including debt, according to third-party news sources.
AthenaHealth was sold in February 2022 by Veritas Capital and Evergreen Coast Capital to Bain Capital and Hellman & Friedman, for $17 billion, or 16x LTM EBITDA.
R1 RCM was taken private in 2024, by Towerbrook and Clayton Dubilier & Rice, in a transaction valuing the company at $8.9 billion, or 14x LTM EBITDA; $3 billion of term loan debt, $1 billion senior secured note, and $5.2 billion of equity proceeds were raised to help fund the $6.6 billion cash purchase price and refinance $2.3 billion of existing debt.
Warburg Pincus and Goldman declined to comment for this story. A representative for Modernizing Medicine did not immediately respond to a request for comment.
This publication has been prepared by Octus, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2025 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.